India Pharma Outlook Team | Thursday, 24 September 2026
Collaboration drives today’s most significant pharma deals and alliances.
Novartis secures exclusive global rights to a preclinical radioligand therapy asset from BoomRay Pharmaceuticals in a deal worth up to 900 million dollars.
At the same time, the Indian Medical Association and Abbott launch Indian Immunization Week to raise adult flu vaccination rates.
These partnerships pair discovery expertise with global scale and clinical guidance with industry support. One advances a precision oncology frontier, whereas the other tackles low immunization that leaves millions unprotected.
Together they show how companies and associations work through structured alliances to close therapeutic and public health gaps.
BoomRay Pharmaceuticals signs an exclusive global licensing agreement with Novartis Pharma AG for an undisclosed preclinical radioligand therapy asset. BoomRay, a China-based clinical-stage biotech, contributes early-stage precision oncology research and development capabilities.
Novartis brings established global scale and expertise in the radiopharmaceutical sector. Under the terms, BoomRay becomes eligible to receive up to 900 million dollars. The package includes an upfront payment plus development, regulatory, and sales milestone payments.
BoomRay can also earn royalties on future global net sales. The agreement aims to unlock the asset’s full potential and accelerate its path to patients worldwide. Radioligand therapies represent an important frontier in oncology.
The partnership expands Novartis’s growing radioligand therapy portfolio by combining external innovation with its own research and development strengths.
Bo Shan, Chief Executive Officer of BoomRay, says “This agreement marks a significant milestone for BoomRay.” Shiva Malek, Global Head of Oncology, Biomedical Research at Novartis, says “Radioligand therapies represent an important frontier in oncology.”
Also Read: Why Clinical Evidence Matters More in MedTech Commercialization
The Indian Medical Association collaborates with Abbott in India to launch Indian Immunization Week from 21 to 27 September. The initiative focuses on preventive healthcare, adult immunization, and annual influenza vaccination. The IMA provides clinical expertise and expert-reviewed guidance. Abbott supplies industry support to raise awareness and equip healthcare professionals.
The partners issue practical recommendations on vaccinating people who experience or recover from fever, including acute febrile illness. The guidance stresses that mild fever should not delay vaccination in most cases. For moderate to severe illness, professionals may defer the shot until recovery and set a clear follow-up date.
India’s adult immunization coverage remains extremely low. The National Sample Survey shows only 1.98 percent of adults aged 18 and above have received adult vaccines. Coverage drops to 0.40 percent among people aged 60 and above.
A 2026 multi-city study finds just 19.7 percent of adults aged 60 and above are aware of influenza, while only 1.4 percent have ever received an influenza vaccine.
Anilkumar J. Nayak, National President of the Indian Medical Association, says: “These recommendations offer a practical roadmap for healthcare professionals.” Parag Sheth, Regional Medical Director at Abbott in India, says: “Prevention is one of the most effective ways to reduce the impact of seasonal influenza.”
Key facts from the immunization drive:
These collaborations illustrate how pharma now advances through alliances. One links biotech’s discovery engine to a global company’s radioligand infrastructure and a 900-million-dollar commitment.
The other joins a medical association’s clinical authority with a company’s outreach capacity to confront documented gaps in adult flu protection. Both focus on concrete outcomes that new treatment options for cancer patients and higher vaccination rates for vulnerable groups, rather than solitary efforts. The pattern shows the organization’s matching complementary strengths to move science and public health forward together.
.jpg)
